ABVX — Price & Forward EBITDA

Forward EBITDA (M)

Float Short %

4.99

Margin Of Safety %

Put/Call OI Ratio

0.47

EPS Next Q Diff

0.45

EPS Last/This Y

2.14

EPS This/Next Y

0.39

Price

102.49

Target Price

146.27

Analyst Recom

1.39

Performance Q

-29.48

Upside

-284.8%

Beta

1.85

Ticker: ABVX

14 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-03-09	ABVX	109.59	0.58	0.26	47125
2026-03-10	ABVX	115.27	0.58	0.29	48428
2026-03-11	ABVX	112.2	0.57	0.27	49501
2026-03-12	ABVX	116.99	0.57	0.17	50208
2026-03-13	ABVX	116.98	0.57	0.17	50208
2026-03-17	ABVX	126.66	0.55	0.38	55271
2026-03-18	ABVX	124.02	0.52	0.49	56359
2026-03-19	ABVX	122.99	0.52	0.35	57956
2026-03-20	ABVX	120.41	0.52	0.51	61006
2026-03-23	ABVX	115.02	0.45	0.93	52849
2026-03-24	ABVX	110.12	0.44	0.29	54945
2026-03-25	ABVX	110.64	0.43	0.36	60938
2026-03-26	ABVX	109.5	0.44	1.34	61731
2026-03-27	ABVX	102.47	0.47	0.85	64554
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

14 items 1 of 1

14 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-03-09	ABVX	109.64	-	-	-4.42
2026-03-10	ABVX	115.15	-	-	-4.42
2026-03-11	ABVX	112.21	-	-	-4.42
2026-03-12	ABVX	116.94	-	-	-4.42
2026-03-13	ABVX	115.66	-	-	-4.42
2026-03-17	ABVX	126.68	-	-	-4.42
2026-03-18	ABVX	124.02	-	-	-4.42
2026-03-19	ABVX	122.90	-	-	-4.42
2026-03-20	ABVX	120.50	-	-	-4.42
2026-03-23	ABVX	115.05	-	-	-4.42
2026-03-24	ABVX	110.14	-	-	-4.42
2026-03-25	ABVX	110.66	-	-	-4.42
2026-03-26	ABVX	109.50	-	-	-4.42
2026-03-27	ABVX	102.49	-	-	-3.46
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

14 items 1 of 1

14 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-03-09	ABVX	0.00	-1.74	4.78
2026-03-10	ABVX	0.00	-1.74	4.78
2026-03-11	ABVX	0.00	-1.74	4.93
2026-03-12	ABVX	0.00	-1.74	4.92
2026-03-13	ABVX	0.00	-1.74	4.92
2026-03-17	ABVX	0.00	-2.86	4.92
2026-03-18	ABVX	0.00	-2.86	4.92
2026-03-19	ABVX	0.00	-2.86	4.92
2026-03-20	ABVX	0.00	-2.86	4.92
2026-03-23	ABVX	0.00	-2.08	4.92
2026-03-24	ABVX	0.00	-2.08	4.92
2026-03-25	ABVX	0.00	-2.08	4.99
2026-03-26	ABVX	0.00	-2.08	4.99
2026-03-27	ABVX	0.00	-2.08	4.99
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

14 items 1 of 1

Last Quarter Act. EPS

-1.19

Avg. EPS Est. Current Quarter

-0.81

Avg. EPS Est. Next Quarter

-0.74

Insider Transactions

Institutional Transactions

-2.08

Beta

1.85

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

31.1

Max Drawdown 5-Year %

Target Price

146.27

P/E

Forward P/E

PEG

P/S

P/B

15.05

P/Free Cash Flow

EPS

-5.41

Average EPS Est. Cur. Y

-3.46

EPS Next Y. (Est.)

-3.08

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

1.42

Return on Equity vs Sector %

-101.2

Return on Equity vs Industry %

-84.9

EPS 1 7Days Diff

-0.2

EPS 1 30Days Diff

-0.18

EBIT Estimation

◆ ABVX Healthcare

$102.47

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

14/20

Pullback

15/25

Volume

3/15

Valuation

10/20

TP/AR

2/10

Options

7/10

RSI

34.4

Range 1M

2.7%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

8/25

Growth

17/30

Estimates

0/20

Inst/Vol

3/15

Options

4/10

EPS Yr

31.2%

EPS NY

18.4%

52W%

68%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +42.7% upside

Quality

3/30

Valuation

10/30

Growth

13/25

Stability

7/10

LT Trend

1/5

Upside

+42.7%

Quality

Abivax SA

Sector: Healthcare

Industry: Biotechnology

Employees:

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as well as in Phase 2b clinical trial to treat patients with Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.

ABVX

Latest News

—

Caricamento notizie per ABVX…

stock quote shares ABVX – Abivax ADR Stock Price stock today

news today ABVX – Abivax ADR stock forecast ,stock prediction 2023 2024 2025

marketwatch ABVX – Abivax ADR yahoo finance google finance

stock history ABVX – Abivax ADR invest stock market

stock prices ABVX premarket after hours

ticker ABVX fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: ABVX

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y